0001193125-24-160146.txt : 20240613 0001193125-24-160146.hdr.sgml : 20240613 20240612204633 ACCESSION NUMBER: 0001193125-24-160146 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240612 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471851754 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 241039844 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 8-K 1 d718851d8k.htm 8-K 8-K
false 0001590877 0001590877 2024-06-12 2024-06-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2024

 

 

REGENXBIO Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37553   47-1851754
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

9804 Medical Center Drive

Rockville, Maryland

     20850
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: 240 552-8181

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   RGNX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 12, 2024, REGENXBIO Inc. (the “Company”) announced that its Board of Directors (the “Board”) accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024. Mr. Mills will continue to serve as a director and has been named Chairman of the Board. Mr. Mills will serve as an advisor to the Company to assist the new Chief Executive Officer until June 30, 2025.

The Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024. In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024, with a term expiring at the Company’s 2025 annual meeting of stockholders or until such time as his successor is duly elected and qualified. Additionally, Daniel Tassé was appointed as the Company’s Lead Independent Director, succeeding Jerry Karabelas.

Mr. Simpson, 62, has been a member of the Company’s senior management team since 2015 and has served as Chief Operating Officer since January 2023. In that role, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing, Quality, Regulatory, and Commercial Operations. Mr. Simpson previously served as the Company’s Chief Operations and Technology Officer. Prior to joining the Company, Mr. Simpson held a series of senior executive operations positions within the life sciences industry, including as Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline and the Human Genome Sciences division of GlaxoSmithKline. Mr. Simpson previously served as Director of Manufacturing Sciences at Biogen. He previously held roles of increasing responsibility with Novo-Nordisk Biochem Inc., and in various senior development and engineer roles at Genentech, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemical engineering and chemistry from the Clarkson College of Technology.

On June 12, 2024, the Company and Mr. Simpson entered into an employment agreement (the “Employment Agreement”) in connection with Mr. Simpson’s promotion to President and Chief Executive Officer. Under the terms of the Employment Agreement, Mr. Simpson initially will be entitled to a base salary of $610,000 and his annual bonus target will be established at a minimum level of 60% of his base salary, which for the 2024 fiscal year will be prorated from July 1, 2024. In addition, on July 1, 2024 Mr. Simpson will be granted stock options and restricted stock units with an aggregate grant date fair value of $2,500,000, of which approximately 75% will consist of stock options and approximately 25% will consist of restricted stock units. The Employment Agreement also provides for certain severance benefits in the event Mr. Simpson is terminated without cause or by reason of death or disability, or if he is terminated or resigns for good reason following a change of control.

Mr. Simpson and his immediate family members are not party to any related party transactions for which disclosure would be required pursuant to Item 404(a) of Regulation S-K. There is no family relationship between Mr. Simpson and any of the Company’s directors or executive officers and no arrangements or understandings with other persons pursuant to which Mr. Simpson was selected as an officer.

On June 12, 2024, the Company and Mr. Mills entered into a Consulting and Separation Agreement (the “Agreement”) for services that he will provide as an advisor to the Company. The Agreement will be effective from July 1, 2024 through June 30, 2025. Under the terms of the Agreement, Mr. Mills will be eligible to receive up to 100% of his targeted bonus payment for the fiscal year ending December 31, 2024. In addition, the Company and Mr. Mills agreed that his outstanding stock options and restricted stock units will continue to vest during his service as an advisor, after which any unvested stock options and restricted stock units will be forfeited. Following the conclusion of his service as an advisor to the Company, Mr. Mills’ stock options will remain exercisable for three months. The Company also will reimburse Mr. Mills’ reasonable legal fees in connection with entering into the Agreement and provide the COBRA coverage for Mr. Mills and his family members through January 30, 2025. Mr. Mills will not receive an initial equity award grant in connection with the commencement of his role as Chairman of the Board and as a non-employee director on the Board, but will be eligible for cash compensation and future annual equity award grants in accordance with the Company’s Compensation Program for Non-Employee Directors.

Item 7.01

Regulation FD Disclosure.

On June 12, 2024, the Company issued a press release announcing the transition of the Company’s President and Chief Executive Officer and reiterating its financial and operational guidance. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
 No. 

   

Description

99.1    Press release issued by REGENXBIO Inc. on June 12, 2024.
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      REGENXBIO INC.
Date: June 12, 2024     By:  

/s/ Patrick J. Christmas II

      Patrick J. Christmas II
Executive Vice President, Chief Legal Officer
 EX-99.1 2 d718851dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

REGENXBIO Announces Leadership Transition

- Curran Simpson, Chief Operating Officer, Appointed as President and CEO

- Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board

ROCKVILLE, Md. — June 12, 2024 — REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO’s Lead Independent Director, a role previously held by Jerry Karabelas, Ph.D. Dr. Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board.

Mr. Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience. As the Chief Operating Officer (COO) at REGENXBIO since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO at Human Genome Sciences (HGS), where he led the integration of HGS into GSK.

“I am honored to serve as REGENXBIO’s next President and CEO,” said Mr. Simpson. “I have been a part of shaping and leading our programs from preclinical to pivotal stages with Ken, and today, our AAV Therapeutics platform is well-positioned to make a meaningful impact. I look forward to our exciting next chapter as I continue to work with Ken and the rest of REGENXBIO’s seasoned management team and Board to further advance our pipeline, drive the commercialization and scale of our business and deliver value for patients, shareholders and our other stakeholders.”

“Leading REGENXBIO since our founding in 2009 has been a privilege,” said Mr. Mills. “We have built the Company into a leader in gene therapy medicines with exciting products progressing through late-stage developments. As we advance our pivotal stage clinical trials, approach commercialization and prepare for our next chapter, now is the right time to transition leadership. Curran and I have worked closely together over the last nine years, and I am confident he brings the R&D, operational, and industry expertise to build on our momentum. I am enthusiastic about the future of REGENXBIO and excited to continue partnering with Curran and working alongside the Board in my role as Chairman.”

“Curran has held various leadership roles since joining the Company in 2015 and consistently demonstrated strategic, commercial and operational expertise and acumen,” said Mr. Fox. “The Board is confident he is the right leader to advance our strategy and oversee our next phase of meaningful value creation as we capitalize on our significant commercial opportunities. The Board and the entire Company would like to thank Ken for his tremendous contributions to REGENXBIO over the past 15 years. Ken pioneered the development of our leading AAV Therapeutics platform, enhancing the landscape of gene therapies, with programs that remain on track to meet our goals. We look forward to continuing to benefit from his deep knowledge of this field, REGENXBIO and our therapeutics pipeline.”

REGENXBIO MAINTAINS FINANCIAL & OPERATIONAL GUIDANCE

The Company today also reiterated its financial guidance previously provided on May 8, 2024: REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $380.5 million as of March 31, 2024 to fund its operations into 2026. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration (including a potential, one-time $200.0 million milestone for achievement of first patient dosed in the first pivotal trial for suprachoroidal delivery for treatment of DR) and the potential monetization of a priority review voucher that may be received for RGX-121.

ABOUT CURRAN SIMPSON

Mr. Simpson has served as the Chief Operating Officer at REGENXBIO since January 2023. In that role, he has been leading key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin® and Avastin®, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemical engineering and chemistry from the Clarkson College of Technology.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s expectations and evaluations of its leadership and management team, future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties,

including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on Form 10-K for the year ended December 31, 2023, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC’s website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Dana Cormack

Corporate Communications

dcormack@regenxbio.com

Investors:

Chris Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com

EX-101.SCH 3 rgnx-20240612.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgnx-20240612_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgnx-20240612_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g718851g0612230059589.jpg GRAPHIC begin 644 g718851g0612230059589.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W6[OK>S"^ M<^"W0 9->7?$/6M7&@");I5CFN#N$+;7,8!].=N2N:Z2>^DU"ZN))HXXFB=T M"K*&S&IX?/;/IVKGM<\2:3I<\=G=O*9G =C#&'"H?4Y[]<#/2N_#TN5IVNSR M\17WGL>K6\\=S LT3!HW M&0:EKD?!FM+J4=Q;P-;R6MOCRWCDRYSR=P[52\5>-M2T3Q+:Z-IVEQ7LMQ&' M3=*5)8DC'IVK@=&7.X(]2->+IJ;.[HKSY_%7CF-&=O!L851DG[2.E7M&\97N MO^%;G4M.TG??P/Y?V4R\,?9J'1DENFL^'TT^V6,L)5F#Y/IBDZ;2OI]XU5BW8ZJBO-H?B'KVJWUW%H7AI;N M&VD*,S3X/7&C45R?\ MPD^J7_A6TU;1='-U<3'YK:23:4'RFTVE>P>VA=)O<[FBN?\8>(9/#7AZ74X8$G=&50CL5!S1=ZOJ0\.V^J6 M-E%.[QB22$L<@$9X]<5G).,>9[&L7S3Y%N=!17,Z;XRTZ]T:2_F<0-"/WT1Z MJ?0>N:F\.:S?ZY')=2V26UF3B%BQ+N/7'I6:JQDTEU-I4*D4W)6L=!17!S^/ MM0/B2^T;3?#SWTUHQ#,MR%R/7!%+=>,_$ME:2W-SX,F2&)2SM]L0X [\"NGV M,SC]O#4[NBN'U'XAQ6G@VR\10Z>\J7,GE^2TFTJ><\X.>14WB+QT-#32TBTZ M2\NM14-'"C[<9QQG')R<4E1FW:PW7@E>YV5%<%_PFOB?_H1;[_O\/\*+#XAW M,FO1Z1JF@7&GW$T9>/?(&S@$C(QT.#S3]A.U_P!1>W@=[17.CQ+(0"NFW#@_ MQ+THK/E9?M(GG%WJ.G:T^JZ5:Q7 6)S%(\SB,*F[!8>X(Z'M5>P\%6.HLYNQ M/;VMK)Y$,T$JR?:D!)W'^Z>1T]>G%=/\0].>*XM[R&V58'!\UXT S)V+8]NY MK$\.2S0&Z*2(HD0 (Q&YSGJH/7 SR*]B&M'VD96/G9U'2Q+I2C=#H(+.W\1: MG;ZHI2TB@9$5NH08$>W\,8JC#H]]K7A/4K>S8;$F1X4D('F$9RH/KC!^H%;V MH7<:Z:]Q?6*7K;@D+S@_*>O4*S[#572_9TBB,3Q%AN9 MCZ@'@#WI_CJUEO?BGH]M;W3VDLL2JL\8RR'<>17?>%]):SMYKRX2);F[?>=B M%2$_A5@2?F'>KESX=TJ\U>#5I[17OK< 13%CE<>V<5TSQ+=9U'V..GAW[%0\ M[GE'BRS\5>&KB(W7B+4KC29B$>Y0\IGJ"O\ ]?FNPT3P]8:?X%DATSQ"\,5T M?-_M+(7:?;GCTZUV=W96]_:R6MU$LT$B[71QD$5EP^#]"@TF?2H[$"QG.9(/ M,8J3^)X_"HE7YX*+T+CA^6;:U.,_L*7_ **A-_W^3_XJMGPWICVE[-(WC.36 M082/L[2*V/\ :X8U:_X5IX0_Z L7_?;_ .-7])\'Z#H5TUSIFGQV\S+L+JS' M(].32E4BU9/\$.-*2=[?BSS+P3) 8/$=I)K2:3--/^[G\P*P^8],D5:U>TGL M-*N;J#XCSW4L2%DA$RY<^GWJ[NZ^'_A:]N9+FXT>!I9#N9@67)]< XJ'_A6W MA$?\P:+_ +[?_&M?;T^;FU^Y&7U>IR\NABZ3]KUGX=:?)<>(YM,G9R6NV@:SN\4/K>ZW;[SAO*^4^A/6 MN6\+>"K+Q1X"AE)^S:A'*_E7*=1SP#ZBO2--\):'I$%S!86"01W*[9E5F.\? MB:N:7H]CHMF+33H!!;@E@@)/)Z]:2KN*?+W']7YFN;8\4\3:YKUCH%QX8\10 M-)*"K07>?OJ/?^+Z]?6O7=*NX+'PE97%PX2*.V4LQ^E7-5T33MJITTHJS_ TH4>2I>3NO MQ/,+K3+S79KO7=.T]$LU?<(C_P M<=3CO7H/A?Q!::U8*(@(IXE"R0_W?I[5 MMP6L-M D$"+'$@PJJ. *H0^'-+M]2;4(;41W1))=&(SGKQG%>?3H2IRYD]]S MU:^+C7AR25K;?\$\J2&2;XG:^L>O?V,0Q_?_ "_-S]WYC6EKEC<+H5ZS_$07 M:B%B;?\ =_O?]G@YYKM;[P'X9U*]EO+S2HY;B5MTCEV^8^O6JX^&WA!6!&BP MY'J[_P"->LZ\&T^UNB/"^KSU7?S9YWX@FBG^#6C/# L"BXQL4DC(W@GGUZUH M>,'6+Q#X)ED8)&JQEF8X 9<\UZ1>>&-&U#2X=,N;")K*$@QPKE54CCMCUI= M2\,Z/K%K#;:A8Q7$4 Q$&SE![$<]J4<1%-:=_P 1O#RL_E^ H\1:)_T%['_P M(3_&O/=3N[:^^->B2VEQ%/&(@-T3AAG:_<5UG_"M?"'_ $!8O^^W_P :O:5X M-\/Z)=BZT[3(8+@ @2#+$ ]<9/%1&5.%VKFDH5)V3MN;84 8 'M13J*YSI& M-&K*0P!&.AKC-5\ VVH^,[37?MLL7E;6,"(,$ITP>P]>***N$Y1V,JL(R6J. M8TS0VU;XC:_97M_/);H"X4'&"2-N.<#;TZ5W>@^$;'0YWGC>6: XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 12, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001590877
Document Type 8-K
Document Period End Date Jun. 12, 2024
Entity Registrant Name REGENXBIO Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-37553
Entity Tax Identification Number 47-1851754
Entity Address, Address Line One 9804 Medical Center Drive
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 552-8181
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol RGNX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S! MH)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4 MQ_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CY MC6@\@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L# M!!0 ( -"ES%@D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2 MO6H0DBBZ0=@S9)[NF:*'3^ M 5!+ P04 " #0IO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-; M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKB MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_' MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'" M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( -"ES%@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ MT*7,6#VE;W+N *P( !$ ( !KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @ T*7,6)E&PO=V]R:W-H965T&UL4$L! A0#% @ T*7,6)^@&_"Q @ X@P T M ( !C0P 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ T*7,6"0>FZ*M ^ $ !H ( ! MOA$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !HQ( %M#;VYT96YT7U1Y<&5S ;72YX;6Q02P4& D "0 ^ @ [1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d718851d8k.htm rgnx-20240612.xsd rgnx-20240612_lab.xml rgnx-20240612_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d718851d8k.htm": { "nsprefix": "rgnx", "nsuri": "http://regenxbio.com/20240612", "dts": { "inline": { "local": [ "d718851d8k.htm" ] }, "schema": { "local": [ "rgnx-20240612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "rgnx-20240612_lab.xml" ] }, "presentationLink": { "local": [ "rgnx-20240612_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-12_to_2024-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d718851d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-12_to_2024-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d718851d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://regenxbio.com//20240612/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-24-160146-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-160146-xbrl.zip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end XML 18 d718851d8k_htm.xml IDEA: XBRL DOCUMENT 0001590877 2024-06-12 2024-06-12 false 0001590877 8-K 2024-06-12 REGENXBIO Inc. DE 001-37553 47-1851754 9804 Medical Center Drive Rockville MD 20850 240 552-8181 false false false false Common Stock, par value $0.0001 per share RGNX NASDAQ false